Workflow from Scientific Research

Patients with a family history of WT or bilateral disease were selected from the German SIOP93-01/GPOH and SIOP2001/GPOH studies. Sufficient tumor and control tissue was available for 129 WT patients. After histological validation of tumor and healthy kidney material, samples were subjected to MLPA for WT-specific copy number alterations and IGF2 imprinting status (BWS-ICR MS-MLPA). Tumor and control DNA was analyzed by either whole exome (WES), whole genome sequencing (WGS), or targeted Sanger sequencing of presumed driver genes.

DOI